Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Nat Commun
2010 Oct 05;1:86. doi: 10.1038/ncomms1090.
Show Gene links
Show Anatomy links
Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.
Ogawa Y
,
Nonaka Y
,
Goto T
,
Ohnishi E
,
Hiramatsu T
,
Kii I
,
Yoshida M
,
Ikura T
,
Onogi H
,
Shibuya H
,
Hosoya T
,
Ito N
,
Hagiwara M
.
???displayArticle.abstract??? Dyrk1A (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A) is a serine/threonine kinase essential for brain development and function, and its excessive activity is considered a pathogenic factor in Down syndrome. The development of potent, selective inhibitors of Dyrk1A would help to elucidate the molecular mechanisms of normal and diseased brains, and may provide a new lead compound for molecular-targeted drug discovery. Here, we report a novel Dyrk1A inhibitor, INDY, a benzothiazole derivative showing a potent ATP-competitive inhibitory effect with IC(50) and K(i) values of 0.24 and 0.18 μM, respectively. X-ray crystallography of the Dyrk1A/INDY complex revealed the binding of INDY in the ATP pocket of the enzyme. INDY effectively reversed the aberrant tau-phosphorylation and rescued the repressed NFAT (nuclear factor of activated T cell) signalling induced by Dyrk1A overexpression. Importantly, proINDY, a prodrug of INDY, effectively recovered Xenopus embryos from head malformation induced by Dyrk1A overexpression, resulting in normally developed embryos and demonstrating the utility of proINDY in vivo.
Figure 5 | Whole-embryo xDyrk1A overexpression assay. (a) In vivo rescue of xDyrk1A overexpression-induced deformity. X. laevis embryos were treated with vehicle alone, TG009 (2.5µM) or proINDY (2.5µM). The embryos were injected with 500pg of -globin, xDyrk1A or kinase-inactive xDyrk1A mRNA (xDyrk-K180R) at the eight-cell stage and incubated until they reached stage 40/41. Arrows, eye deformity; arrowheads, head deformity. (b) Rescue rate of embryo deformity. X. laevis embryos were treated with either proINDY (2.5µM) or vehicle alone and injected with 250pg or 500pg of xDyrk1A mRNA.
Uninjected embryos were used as controls. The percentages of normal embryos, embryos with mild deformity and embryos with severe deformity in
each experimental group are depicted in green, yellow and orange, respectively. The embryos were categorized into normal, mild deformity and severe
deformity groups according to the degree of eye, head and trunk deformity, as illustrated in Supplementary Figure S6. The mean percentage from two
independent experiments and the range for each group are shown. The numbers of embryos used were as follows: for vehicle alone and uninjected: 28 and
37 for the first and second experiments, respectively; vehicle alone and 250pg mRNA: 35 and 29; vehicle alone and 500pg mRNA: 41 and 27; proINDY
and uninjected: 39 and 35; proINDY and 250pg mRNA: 23 and 44; and proINDY and 500pg mRNA: 34 and 29. Error bars indicate the range. (c) Reversal
of downregulation of differential neural markers. X. laevis embryos treated with proINDY (2.5µM) or vehicle alone were injected with xDyrk1A mRNA
(500pg) and grew until stage 17. Expression of depicted differentiation markers was analysed by RT–PCR. xOdc is an internal control. Lanes: −RT, negative control without reverse transcriptase; +RT, uninjected and non-treated.
Ahn,
DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects.
2006, Pubmed
Ahn,
DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects.
2006,
Pubmed
Altafaj,
Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.
2001,
Pubmed
Altafaj,
Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome.
2008,
Pubmed
Antonarakis,
The challenge of Down syndrome.
2006,
Pubmed
Arqué,
Impaired spatial learning strategies and novel object recognition in mice haploinsufficient for the dual specificity tyrosine-regulated kinase-1A (Dyrk1A).
2008,
Pubmed
Arron,
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21.
2006,
Pubmed
Bain,
The specificities of protein kinase inhibitors: an update.
2003,
Pubmed
Bain,
The selectivity of protein kinase inhibitors: a further update.
2007,
Pubmed
Becker,
Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases.
1998,
Pubmed
Benavides-Piccione,
Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse.
2005,
Pubmed
Branchi,
Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration.
2004,
Pubmed
Brunger,
Version 1.2 of the Crystallography and NMR system.
2007,
Pubmed
Canagarajah,
Activation mechanism of the MAP kinase ERK2 by dual phosphorylation.
1997,
Pubmed
Crabtree,
NFAT signaling: choreographing the social lives of cells.
2002,
Pubmed
Dowjat,
Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
2007,
Pubmed
Ferrer,
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
2005,
Pubmed
Fotaki,
Haploinsufficiency of Dyrk1A in mice leads to specific alterations in the development and regulation of motor activity.
2004,
Pubmed
Fotaki,
Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice.
2002,
Pubmed
Fuentes,
An investigation on the central effects of harmine, harmaline and related beta-carbolines.
1971,
Pubmed
Fukuhara,
Utilization of host SR protein kinases and RNA-splicing machinery during viral replication.
2006,
Pubmed
Gardiner,
Molecular basis of pharmacotherapies for cognition in Down syndrome.
2010,
Pubmed
Guedj,
Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A.
2009,
Pubmed
Guimera,
Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome.
1999,
Pubmed
Guimerá,
A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region.
1996,
Pubmed
Gwack,
A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT.
2006,
Pubmed
Göckler,
Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
2009,
Pubmed
Himpel,
Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A.
2001,
Pubmed
Hyodo-Miura,
Involvement of NLK and Sox11 in neural induction in Xenopus development.
2002,
Pubmed
,
Xenbase
Kao,
Calcineurin/NFAT signaling is required for neuregulin-regulated Schwann cell differentiation.
2009,
Pubmed
Kim,
Inhibition of monoamine oxidase A by beta-carboline derivatives.
1997,
Pubmed
Kimura,
The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
2007,
Pubmed
Korbel,
The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies.
2009,
Pubmed
Laguna,
The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development.
2008,
Pubmed
Leder,
Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional properties.
2003,
Pubmed
Leder,
Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases.
1999,
Pubmed
Liu,
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome.
2008,
Pubmed
Mandel,
Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases.
2008,
Pubmed
Martínez de Lagrán,
Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction.
2004,
Pubmed
McCoy,
Phaser crystallographic software.
2007,
Pubmed
Mott,
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
2009,
Pubmed
Muraki,
Manipulation of alternative splicing by a newly developed inhibitor of Clks.
2004,
Pubmed
,
Xenbase
Noll,
DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase.
2009,
Pubmed
Olson,
Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice.
2007,
Pubmed
Patra,
Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specificity and interaction with membrane lipid rafts.
2008,
Pubmed
Ryoo,
DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease.
2007,
Pubmed
Satoh,
Nemo-like kinase-myocyte enhancer factor 2A signaling regulates anterior formation in Xenopus development.
2007,
Pubmed
,
Xenbase
Sebrié,
Increased dosage of DYRK1A and brain volumetric alterations in a YAC model of partial trisomy 21.
2008,
Pubmed
Sherman,
Epidemiology of Down syndrome.
2007,
Pubmed
Shindoh,
Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene from "the Down syndrome critical region" of chromosome 21.
1996,
Pubmed
Smith,
Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome.
1997,
Pubmed
Son,
Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors.
2008,
Pubmed
Song,
Isolation of human and murine homologues of the Drosophila minibrain gene: human homologue maps to 21q22.2 in the Down syndrome "critical region".
1996,
Pubmed
Wegiel,
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
2008,
Pubmed
Wiseman,
Down syndrome--recent progress and future prospects.
2009,
Pubmed
Wisniewski,
Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome.
1985,
Pubmed
Woods,
The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase.
2001,
Pubmed
Yu,
A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions.
2010,
Pubmed
